Work

A phase Ib/III randomized double-blinded placebo-controlled study of suvemcitug combined with trifluridine/tipiracil for refractory metastatic colorectal cancer.

Year: 2026

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.tps3674

Authors: Ying Yuan, Yanhong Gu, Shuqin Ni, Zuoxing Niu, Rong-Bo Lin, Ting Deng, Yanqiao Zhang, Shuang Hu, Jiajing Zhang, Zewen Zhu, Xiyang Sun, Ke-Feng Ding

Institutions: Second Affiliated Hospital of Zhejiang University, Zhejiang University, Jiangsu Province Hospital, Shandong First Medical University, Shandong Tumor Hospital, Fujian Provincial Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Third Affiliated Hospital of Harbin Medical University, Simcere Pharmaceutical (China)

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162686241

FWCI:

Cites:

Cited by:

Related to: